LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
30 hedge funds and large institutions have $356K invested in LakeShore Biopharma Warrants in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
17% more capital invested
Capital invested by funds: $304K → $356K (+$51.7K)
6.36% more ownership
Funds ownership: 0% → 6.36% (+6.4%)
3% less funds holding
Funds holding: 31 → 30 (-1)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.21K |
| 2 |
AC
Athos Capital
Hong Kong
|
-$1.1K |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$781 |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$470 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$234 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MC
26
Meteora Capital
Boca Raton,
Florida
| $1.03K | – | – | – |
|
|
SIA
27
SkyView Investment Advisors
Shrewsbury,
New Jersey
| $1K | – | – | – |
|
|
AA
28
Ancora Advisors
Cleveland,
Ohio
| $208 | – | – | – |
|
|
HIM
29
HGC Investment Management
Toronto,
Ontario, Canada
| $206 | – | – | – |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $5 | – | – | – |
|
|
LCM
31
Landscape Capital Management
Englewood,
New Jersey
| – | -$470 | -10,000 | Closed |
|
|
32
UBS Group
Zurich,
Switzerland
| – | -$234 | -4,492 | -100% |
|
LSBPW Hedge Fund Activity: Q3 2023 in Review
30 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q3 2023, worth a combined $356K — up 17% from $304K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LSBPW and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Cowen and Company, adding an estimated $5. The largest seller was Radcliffe Capital Management, cutting an estimated $2.21K.
- 30 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q3 2023, down from 31 in Q2 2023.
- Funds reported $356K of LakeShore Biopharma Warrants stock for Q3 2023, up 17% quarter-over-quarter.
- 0 funds opened new LakeShore Biopharma Warrants positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest LakeShore Biopharma Warrants buyer in Q3 2023 was Cowen and Company, an estimated $5 added.
- The largest LakeShore Biopharma Warrants seller in Q3 2023 was Radcliffe Capital Management, an estimated $2.21K sold.
Based on aggregated 13F filings for Q3 2023.